The use of nanoparticles for targeted drug delivery in non-small cell lung cancer
Lung cancer is a global health problem affecting millions of people each year. Non-small cell lung cancer (NSCLC) is the most common form of lung cancer with various conventional treatment available in the clinic. Application of these treatments alone often results in high rates of cancer reoccurren...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1154318/full |
| _version_ | 1797871834890240000 |
|---|---|
| author | Jessica E. Holder Christopher Ferguson Elisabete Oliveira Elisabete Oliveira Carlos Lodeiro Carlos Lodeiro Carol M. Trim Lee J. Byrne Emilia Bertolo Cornelia M. Wilson |
| author_facet | Jessica E. Holder Christopher Ferguson Elisabete Oliveira Elisabete Oliveira Carlos Lodeiro Carlos Lodeiro Carol M. Trim Lee J. Byrne Emilia Bertolo Cornelia M. Wilson |
| author_sort | Jessica E. Holder |
| collection | DOAJ |
| description | Lung cancer is a global health problem affecting millions of people each year. Non-small cell lung cancer (NSCLC) is the most common form of lung cancer with various conventional treatment available in the clinic. Application of these treatments alone often results in high rates of cancer reoccurrence and metastasis. In addition, they can cause damage to healthy tissues, resulting in many adverse effects. Nanotechnology has emerged as a modality for the treatment of cancer. When used in combination with nanoparticles, it is possible to improve the pharmacokinetic and pharmacodynamic profiles of pre-existing drugs used in cancer treatment. Nanoparticles have physiochemical properties such as small size which allowing passage through challenging areas of the body, and large surface area allows for higher doses of drugs to be brought to the tumor site. Nanoparticles can be functionalized which involves modifying the surface chemistry of the particles and allows for the conjugation of ligands (small molecules, antibodies, and peptides). Ligands can be chosen for their ability to target components that are specific to or are upregulated in cancer cells, such as targeting receptors on the tumor surface that are highly expressed in the cancer. This ability to precisely target the tumor can improve the efficacy of drugs and decrease toxic side effects. This review will discuss approaches used for targeting drugs to tumors using nanoparticles, provide examples of how this has been applied in the clinic and highlight future prospects for this technology. |
| first_indexed | 2024-04-10T00:50:21Z |
| format | Article |
| id | doaj.art-ff4657231f1c4ca38df728b6c2c7d2dc |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T00:50:21Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-ff4657231f1c4ca38df728b6c2c7d2dc2023-03-13T14:46:10ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-03-011310.3389/fonc.2023.11543181154318The use of nanoparticles for targeted drug delivery in non-small cell lung cancerJessica E. Holder0Christopher Ferguson1Elisabete Oliveira2Elisabete Oliveira3Carlos Lodeiro4Carlos Lodeiro5Carol M. Trim6Lee J. Byrne7Emilia Bertolo8Cornelia M. Wilson9Canterbury Christ Church University, School of Psychology and Life Sciences, Life Sciences Industry Liaison Lab, Sandwich, United KingdomCanterbury Christ Church University, School of Psychology and Life Sciences, Life Sciences Industry Liaison Lab, Sandwich, United KingdomBIOSCOPE Research Group, Laboratório Associado para a Química Verde- Rede de Química e Tecnologia (LAQV- REQUIMTE), Chemistry Department, NOVA School of Science and Technology, Universidade NOVA de Lisboa, Caparica, PortugalPROTEOMASS Scientific Society, Madan Parque, Rua dos Inventores, Caparica, PortugalBIOSCOPE Research Group, Laboratório Associado para a Química Verde- Rede de Química e Tecnologia (LAQV- REQUIMTE), Chemistry Department, NOVA School of Science and Technology, Universidade NOVA de Lisboa, Caparica, PortugalPROTEOMASS Scientific Society, Madan Parque, Rua dos Inventores, Caparica, PortugalCanterbury Christ Church University, School of Psychology and Life Sciences, Life Sciences Industry Liaison Lab, Sandwich, United KingdomCanterbury Christ Church University, School of Psychology and Life Sciences, Life Sciences Industry Liaison Lab, Sandwich, United KingdomCanterbury Christ Church University, School of Psychology and Life Sciences, Life Sciences Industry Liaison Lab, Sandwich, United KingdomCanterbury Christ Church University, School of Psychology and Life Sciences, Life Sciences Industry Liaison Lab, Sandwich, United KingdomLung cancer is a global health problem affecting millions of people each year. Non-small cell lung cancer (NSCLC) is the most common form of lung cancer with various conventional treatment available in the clinic. Application of these treatments alone often results in high rates of cancer reoccurrence and metastasis. In addition, they can cause damage to healthy tissues, resulting in many adverse effects. Nanotechnology has emerged as a modality for the treatment of cancer. When used in combination with nanoparticles, it is possible to improve the pharmacokinetic and pharmacodynamic profiles of pre-existing drugs used in cancer treatment. Nanoparticles have physiochemical properties such as small size which allowing passage through challenging areas of the body, and large surface area allows for higher doses of drugs to be brought to the tumor site. Nanoparticles can be functionalized which involves modifying the surface chemistry of the particles and allows for the conjugation of ligands (small molecules, antibodies, and peptides). Ligands can be chosen for their ability to target components that are specific to or are upregulated in cancer cells, such as targeting receptors on the tumor surface that are highly expressed in the cancer. This ability to precisely target the tumor can improve the efficacy of drugs and decrease toxic side effects. This review will discuss approaches used for targeting drugs to tumors using nanoparticles, provide examples of how this has been applied in the clinic and highlight future prospects for this technology.https://www.frontiersin.org/articles/10.3389/fonc.2023.1154318/fullnanoparticleslung cancerdrug deliverytherapeuticscancer |
| spellingShingle | Jessica E. Holder Christopher Ferguson Elisabete Oliveira Elisabete Oliveira Carlos Lodeiro Carlos Lodeiro Carol M. Trim Lee J. Byrne Emilia Bertolo Cornelia M. Wilson The use of nanoparticles for targeted drug delivery in non-small cell lung cancer Frontiers in Oncology nanoparticles lung cancer drug delivery therapeutics cancer |
| title | The use of nanoparticles for targeted drug delivery in non-small cell lung cancer |
| title_full | The use of nanoparticles for targeted drug delivery in non-small cell lung cancer |
| title_fullStr | The use of nanoparticles for targeted drug delivery in non-small cell lung cancer |
| title_full_unstemmed | The use of nanoparticles for targeted drug delivery in non-small cell lung cancer |
| title_short | The use of nanoparticles for targeted drug delivery in non-small cell lung cancer |
| title_sort | use of nanoparticles for targeted drug delivery in non small cell lung cancer |
| topic | nanoparticles lung cancer drug delivery therapeutics cancer |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1154318/full |
| work_keys_str_mv | AT jessicaeholder theuseofnanoparticlesfortargeteddrugdeliveryinnonsmallcelllungcancer AT christopherferguson theuseofnanoparticlesfortargeteddrugdeliveryinnonsmallcelllungcancer AT elisabeteoliveira theuseofnanoparticlesfortargeteddrugdeliveryinnonsmallcelllungcancer AT elisabeteoliveira theuseofnanoparticlesfortargeteddrugdeliveryinnonsmallcelllungcancer AT carloslodeiro theuseofnanoparticlesfortargeteddrugdeliveryinnonsmallcelllungcancer AT carloslodeiro theuseofnanoparticlesfortargeteddrugdeliveryinnonsmallcelllungcancer AT carolmtrim theuseofnanoparticlesfortargeteddrugdeliveryinnonsmallcelllungcancer AT leejbyrne theuseofnanoparticlesfortargeteddrugdeliveryinnonsmallcelllungcancer AT emiliabertolo theuseofnanoparticlesfortargeteddrugdeliveryinnonsmallcelllungcancer AT corneliamwilson theuseofnanoparticlesfortargeteddrugdeliveryinnonsmallcelllungcancer AT jessicaeholder useofnanoparticlesfortargeteddrugdeliveryinnonsmallcelllungcancer AT christopherferguson useofnanoparticlesfortargeteddrugdeliveryinnonsmallcelllungcancer AT elisabeteoliveira useofnanoparticlesfortargeteddrugdeliveryinnonsmallcelllungcancer AT elisabeteoliveira useofnanoparticlesfortargeteddrugdeliveryinnonsmallcelllungcancer AT carloslodeiro useofnanoparticlesfortargeteddrugdeliveryinnonsmallcelllungcancer AT carloslodeiro useofnanoparticlesfortargeteddrugdeliveryinnonsmallcelllungcancer AT carolmtrim useofnanoparticlesfortargeteddrugdeliveryinnonsmallcelllungcancer AT leejbyrne useofnanoparticlesfortargeteddrugdeliveryinnonsmallcelllungcancer AT emiliabertolo useofnanoparticlesfortargeteddrugdeliveryinnonsmallcelllungcancer AT corneliamwilson useofnanoparticlesfortargeteddrugdeliveryinnonsmallcelllungcancer |